BRD3 and carcinoma: This comprehensive analysis investigated the clinical and molecular characteristics of NC, including the median age at diagnosis (23.6 years, range: 18 days to 80 years), gender distribution (52% female), tumor locations (thorax: 51%, head and neck: 41%, bone and soft tissue: 6%, and kidney: 1%), NUTM1 fusion partners (78% BRD4::NUTM1, 15% BRD3::NUTM1, and 6% NSD3::NUTM1), and histological types (54% carcinoma without squamous differentiation and 33% carcinoma with squamous differentiation) (4).